NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Nephroplus Expands in Philippines with Two Dialysis Center Acquisitions for INR 11.24 Crores
Nephrocare Health Services Limited, through its Philippines-based step-down subsidiary, has executed Asset Transfer Agreements to acquire two dialysis centers. The company is acquiring assets from Northern Mindanao Dialysis Clinic for approximately INR 4.25 Crores and Aliaga Hemodialysis Centre for approximately INR 6.99 Crores. This strategic move strengthens Nephroplus's international footprint in the Southeast Asian healthcare market. The total investment for these acquisitions is approximately INR 11.24 Crores.
முக்கிய அம்சங்கள்
Acquisition of assets from Northern Mindanao Dialysis Clinic Inc. for PHP 27.4 million (approx. INR 4.25 Crores).Acquisition of assets from Aliaga Hemodialysis Centre Inc. for PHP 44.8 million (approx. INR 6.99 Crores).Total investment for the two Philippines-based centers stands at approximately INR 11.24 Crores.The transactions were executed through Nephrocare Health Care Services Philippines Inc., a wholly-owned step-down subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive indicator of the company's ability to scale internationally. Monitor the impact of these acquisitions on the company's consolidated margins and revenue growth in the next few quarters.
Nephroplus Approves Overseas Investments & Re-appoints BDO India as Internal Auditor
Nephrocare Health Services Limited (Nephroplus) announced several key decisions from its board meeting held on May 19, 2026. The company approved a further investment of up to Rs. 10 Crore in its wholly-owned Nepalese subsidiary to support business operations and working capital. Additionally, the board granted in-principle approval to provide collateral/security support aggregating up to Rs. 70 Crore each for its subsidiaries in Singapore and Saudi Arabia to help them secure credit facilities from overseas banks. Lastly, M/s. BDO India LLP was re-appointed as the Internal Auditor for the financial year 2026-27.
முக்கிய அம்சங்கள்
Approved up to Rs. 10 Crore equity investment in Nephrocare Health Services Nepal Private Limited.Granted in-principle approval for Rs. 70 Crore collateral support for the Singapore overseas subsidiary.Granted in-principle approval for Rs. 70 Crore collateral support for the Saudi Arabia subsidiary/JV.Re-appointed M/s. BDO India LLP as the Internal Auditor for the financial year 2026-27.Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the performance of the company's overseas subsidiaries in Nepal, Singapore, and Saudi Arabia, as Nephroplus is committing significant financial backing and capital of over Rs. 150 Crore to these markets to Rs. 150 Crores in total exposure to these markets.
Nephroplus to Provide ₹140 Cr in Guarantees and ₹10 Cr Investment for Global Subsidiaries
Nephrocare Health Services (Nephroplus) has authorized significant financial support for its international expansion, totaling ₹150 crore. The board approved a ₹10 crore investment in its Nepal subsidiary and ₹70 crore each in collateral/security support for its Singapore and Saudi Arabian ventures. These guarantees are intended to help the overseas units secure credit facilities for their respective business operations. This move demonstrates a clear commitment to scaling the company's footprint in the Middle East and Southeast Asia.
முக்கிய அம்சங்கள்
Approved ₹10 Crore investment in Nepal subsidiary (NP Nepal) for working capital and operations.Provided ₹70 Crore collateral support for Singapore subsidiary to facilitate overseas credit facilities.Provided ₹70 Crore collateral support for Saudi Arabia subsidiary/JV for credit facility access.Total financial backing for international operations amounts to ₹150 Crore across three regions.Re-appointed BDO India LLP as Internal Auditor for the 2026-27 financial year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the performance of these international units as the company is taking on significant contingent liabilities. Review the FY26 audited results to ensure the domestic business remains robust enough to support this global scaling.
NephroPlus FY26 Revenue Surges 32% to ₹999 Cr; Adjusted PAT Jumps 75%
Nephrocare Health Services (NephroPlus) reported a robust performance for FY26, with revenue reaching ₹998.8 crore, driven by a 16.6% increase in treatment volumes. The company's international operations saw significant growth, now contributing 41.8% of total revenue compared to 31.8% in the previous year. Adjusted PAT witnessed a stellar growth of 74.6% YoY to ₹128.3 crore, supported by improved margins and operational efficiencies. The company maintained a healthy Adjusted ROCE of 22.8%, reflecting disciplined capital allocation and the scalability of its dialysis platform.
முக்கிய அம்சங்கள்
FY26 Revenue grew 32.2% YoY to ₹998.8 crore, while Q4 FY26 revenue rose 21.2% to ₹265.6 crore.Adjusted PAT for the full year surged 74.6% to ₹128.3 crore, with Adjusted EBITDA margins improving to 23.8%.International revenue contribution increased to 41.8% in FY26, up from 31.8% in FY25, boosting Revenue Per Treatment (RPT) by 13.3%.Total treatments delivered in FY26 reached 3.84 million, a 16.6% increase over the previous year.Adjusted ROCE improved by 290 basis points to 22.8%, indicating strong capital efficiency and platform leverage.
👀 கவனிக்க வேண்டியவை
Investors should note the strong operating leverage and successful international expansion which is driving higher margins. The company's transition to a profitable, high-growth healthcare platform makes it a key stock to watch in the specialized medical services sector.
Nephroplus Approves ₹150 Cr in Global Investments & Guarantees; Reports FY26 Results
Nephrocare Health Services (Nephroplus) has approved a significant international expansion strategy, including a ₹10 crore direct investment in its Nepal subsidiary for working capital. The board also granted in-principle approval for providing collateral support of ₹70 crore each for its Singapore and Saudi Arabian operations to facilitate overseas credit facilities. While the company reported a standalone net loss for the fiscal year ended March 31, 2026, these financial commitments of ₹150 crore indicate an aggressive push into global markets. Additionally, BDO India LLP has been re-appointed as the internal auditor for FY 2026-27 to maintain governance standards.
முக்கிய அம்சங்கள்
Approved ₹10 Crore investment in Nepal subsidiary for business operations and working capital.Authorized ₹70 Crore collateral support for Singapore subsidiary to access overseas bank credit.Authorized ₹70 Crore collateral support for Saudi Arabia JV/subsidiary for credit facilities.Audited FY26 standalone results reported a net loss for the period.Re-appointed BDO India LLP as Internal Auditors for the 2026-27 financial year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of international expansion and whether the ₹140 crore in guarantees leads to profitable scaling in Singapore and Saudi Arabia. It is crucial to evaluate the consolidated results to see if international growth offsets the reported standalone losses.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
NephroPlus Subsidiary Acquires Philippines Dialysis Center Assets for PHP 89.6 Million
Nephrocare Health Services Limited, through its step-down subsidiary in the Philippines, has entered into an Asset Transfer Agreement to acquire a dialysis center in Orani, Bataan. The acquisition involves a total consideration of PHP 89.6 million (approximately ₹13.2 crore) paid to Orani Hemodialysis Center Inc. This move aligns with the company's strategy to expand its international footprint in the renal care segment. The transaction is an arm's length deal with a non-related party, focusing on asset acquisition rather than equity.
முக்கிய அம்சங்கள்
Acquisition of dialysis center assets in Orani, Bataan, Philippines for PHP 89,600,000Executed via step-down wholly-owned subsidiary Nephrocare Health Care Services, Philippines Inc.Transaction involves the transfer of identified assets from Orani Hemodialysis Center Inc.The deal is a non-related party transaction, ensuring no conflict of interest with promotersStrengthens NephroPlus's presence in the Southeast Asian healthcare market
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward international scaling; monitor the company's ability to integrate and improve margins in the Philippines market.
NephroPlus Q3 FY26: Maiden Earnings Call Highlights Expansion Across 290+ Cities
Nephrocare Health Services (NephroPlus) conducted its first earnings call post-listing on December 17, 2025, detailing its dominant position with over 300 hospital partners across 25 states. The company highlighted its transition from 11 years of EBITDA losses to a profitable scale-driven model, capitalizing on the 80% unorganized Indian dialysis market. Management emphasized a 'shop-in-shop' model and selective PPP projects in 4 states to drive growth. With a presence in 290+ cities, the company aims to leverage its fixed-capacity model to capture rising demand from chronic kidney disease.
முக்கிய அம்சங்கள்
Operates a massive network across 25 Indian states and 290+ cities with over 300 hospital partnersAchieved operating leverage after 11 years of being EBITDA negative by reaching critical scaleSignificant growth runway as 80% of the Indian dialysis market remains unorganized and hospital-runDiversified revenue through selective PPP projects in 4 states: Andhra, Bihar, Uttarakhand, and KarnatakaBusiness model focuses on high-frequency, life-sustaining care with a cap of ~85% utilization for emergency capacity
👀 கவனிக்க வேண்டியவை
Investors should monitor the pace of new hospital tie-ups and the transition of the unorganized market to organized players. The stock offers a unique monoline healthcare play with high recurring revenue and significant barriers to entry due to scale requirements.
Nephroplus Subsidiary Acquires Philippine Dialysis Center Assets for PHP 49.4 Million
Nephrocare Health Services Limited (Nephroplus) has announced that its step-down Philippine subsidiary has entered into an Asset Transfer Agreement to acquire a dialysis center. The acquisition involves identified assets from Laurel Kidney Care Dialysis Centre Inc. located in Batangas, Philippines. The total consideration for the transaction is PHP 49,400,000. This move marks a strategic expansion of the company's international footprint in the specialized healthcare and dialysis services market.
முக்கிய அம்சங்கள்
Acquisition of dialysis center assets in Laurel, Batangas, Philippines for PHP 49,400,000Executed through step-down wholly-owned subsidiary Nephrocare Health Care Services Philippines Inc.Asset Transfer Agreement (ATA) signed with Laurel Kidney Care Dialysis Centre Inc. on February 12, 2026The transaction is not a related party transaction and involves no special rights like board seats
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in the company's international expansion strategy. Monitor the company's ability to integrate these assets and scale its operations in the Southeast Asian market.
NephroPlus Reports 9M FY26 Revenue of ₹733.2 Cr with 23.9% Adj. EBITDA Margin
Nephrocare Health Services (NephroPlus) reported a strong financial performance for 9M FY26, achieving revenue of ₹733.2 crore and an adjusted EBITDA of ₹175.4 crore. The company maintains a dominant position as Asia's largest dialysis network with 521 clinics globally and a >50% market share in the Indian organized sector. Notably, international operations now contribute approximately 41% of total revenue, reflecting successful expansion into higher-margin markets like Uzbekistan and the Philippines. The company also reported a healthy annualized pre-tax ROCE of 24.7%.
முக்கிய அம்சங்கள்
9M FY26 Revenue from operations reached ₹733.2 Cr with an adjusted EBITDA margin of 23.9%.Global network expanded to 521 clinics across 325+ cities, serving over 36,000 patients.International revenue salience stands at ~41%, benefiting from higher price points in overseas markets.Achieved an annualized pre-tax ROCE of 24.7% and a 31% revenue CAGR between FY23-25.Entry into Saudi Arabia is underway with the first clinic in Riyadh operations-ready and license pending.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain high margins as it scales its international footprint, particularly in Saudi Arabia. The strong ROCE and dominant market share in India make it a key player to watch in the healthcare services sector.
NephroPlus Q3 FY26 Revenue Up 31.7% YoY to ₹259.7 Cr; Adj. PAT Surges 71.3%
NephroPlus reported a robust Q3 FY26 performance with consolidated revenue growing 31.7% YoY to ₹259.7 crore, supported by a 17.7% increase in treatment volumes. Adjusted PAT witnessed a significant jump of 71.3% YoY to ₹34.4 crore, while Adjusted EBITDA margins expanded by 190 bps to 24.3%. The growth is largely attributed to a strategic shift towards international markets, which now contribute 41.1% of total revenue. The company also achieved a healthy annualized RoCE of 24.7%, up from 18.7% in the previous year.
முக்கிய அம்சங்கள்
Revenue for Q3 FY26 grew 31.7% YoY to ₹259.7 crore; 9M FY26 revenue reached ₹733.2 crore.Adjusted PAT for Q3 FY26 surged 71.3% YoY to ₹34.4 crore with a margin of 13.3%.International revenue contribution increased from 29.5% to 41.1% YoY, boosting revenue per treatment by 17%.Treatment volumes grew 17.7% YoY to 9.83 lakh treatments in Q3 FY26.Annualized RoCE (Pre-Tax) improved by 600 bps to 24.7% for FY26.
👀 கவனிக்க வேண்டியவை
The company demonstrates strong operational leverage and successful execution of its international expansion strategy, which is margin-accretive. Investors should maintain a positive outlook given the scalable asset-light model and improving return ratios.
Nephroplus Q3 Revenue Rises 16% YoY to ₹1,607 Mn; PAT Recovers to ₹84.5 Mn
Nephrocare Health Services (Nephroplus) reported a 16.2% YoY revenue growth for Q3 FY26, reaching ₹1,606.64 million. The company returned to a profit of ₹84.52 million this quarter, successfully recovering from a heavy loss in Q2 FY26 which was primarily caused by a one-time non-cash interest expense of ₹371.89 million. This marks the company's first financial disclosure since listing on the BSE and NSE in December 2025. Additionally, the board has strengthened its internal governance by designating Mr. Ravindra Tiwari as Senior Management Personnel.
முக்கிய அம்சங்கள்
Revenue from operations increased 16.2% YoY to ₹1,606.64 million in Q3 FY26.Quarterly PAT stood at ₹84.52 million, a significant recovery from the ₹324.14 million loss in Q2 FY26.A non-recurring, non-cash interest expense of ₹371.89 million impacted the nine-month bottom line.Completed IPO of 18.94 million shares in December 2025 at an issue price of ₹460 per share.Mr. Ravindra Tiwari, Head of Internal Audit with 18 years experience, designated as Senior Management Personnel.
👀 கவனிக்க வேண்டியவை
Investors should view the return to profitability positively as the previous quarter's loss was due to a non-recurring accounting item. The steady revenue growth post-listing indicates a healthy operational trajectory in the dialysis services segment.
Nephroplus Q3 FY26: Revenue Up 16% YoY to ₹1,606M; Returns to Profitability Post-IPO
Nephrocare Health Services (Nephroplus) reported a 16.2% YoY revenue growth to ₹1,606.64 million for the quarter ended December 31, 2025. The company posted a net profit of ₹84.52 million, a significant recovery from the ₹324.14 million loss in the preceding quarter, which was skewed by non-recurring finance costs. This is the company's first financial disclosure since its listing in December 2025, showing normalized operations. Additionally, the board appointed Ravindra Tiwari as a Senior Management Personnel to lead internal audit and risk management.
முக்கிய அம்சங்கள்
Revenue from operations increased 16.2% YoY to ₹1,606.64 million in Q3 FY26.Net profit stood at ₹84.52 million for Q3, recovering from a ₹324.14 million loss in Q2 FY26.Finance costs normalized to ₹39.64 million in Q3 from ₹410.47 million in Q2 (which included non-cash FVTPL charges).9M FY26 revenue reached ₹4,654.10 million compared to ₹3,985.85 million in the previous year.Successfully completed IPO in Dec 2025, raising fresh capital through 7.69 million new shares.
👀 கவனிக்க வேண்டியவை
Investors should view the return to profitability as a positive sign that the one-time pre-IPO financial adjustments are now behind the company. The steady revenue growth suggests strong demand in the dialysis segment, making it a key stock to watch for healthcare sector exposure.
Nephroplus Shareholders Approve Director Re-appointment and Auditor Selection with 99.99% Majority
Nephrocare Health Services Limited (Nephroplus) has announced the successful passage of two key resolutions via postal ballot with near-unanimous shareholder support. The re-appointment of Mr. Om Prakash Manchanda as an Independent Director was approved with 99.9996% of the 82.79 million valid votes cast. Additionally, the appointment of M/s Makarand M. Joshi & Co. as Secretarial Auditor received 99.9997% approval. These results reflect strong alignment between the company's leadership and its shareholder base, including 100% support from institutional investors.
முக்கிய அம்சங்கள்
Mr. Om Prakash Manchanda re-appointed as Independent Director with 99.9996% votes in favor.M/s Makarand M. Joshi & Co. appointed as Secretarial Auditor with 99.9997% approval.Total valid votes cast reached 82,790,430, representing approximately 82.51% of the total shareholding.Institutional investors cast 19,532,271 votes, all 100% in favor of both resolutions.Promoter group participation was high at 97.07% of their holdings, voting entirely in favor.
👀 கவனிக்க வேண்டியவை
Investors should view these results as a sign of corporate governance stability and strong shareholder confidence. No immediate action is required as these are routine but essential management approvals.
Nephroplus Subsidiary Acquires Philippines Dialysis Center for PHP 37.7 Million
Nephrocare Health Services Limited (Nephroplus) has announced that its step-down subsidiary in the Philippines has acquired a dialysis center in Cauayan. The deal involves an Asset Transfer Agreement with Dialysis Center of Cauayan Inc. for a total consideration of PHP 37,721,600. A separate Memorandum of Agreement ensures joint operations during the transition period for licensing and accreditation. This acquisition marks a strategic expansion of the company's international service network in Southeast Asia.
முக்கிய அம்சங்கள்
Total acquisition cost of PHP 37,721,600 for assets in Cauayan, PhilippinesAgreement signed with Dialysis Center of Cauayan Inc. (DCCI) on January 26, 2026Includes a joint operation agreement for the interim period pending license transfersExpansion executed through step-down subsidiary Nephrocare Health Care Services, Philippines Inc.
👀 கவனிக்க வேண்டியவை
This expansion indicates a focus on growing the international footprint in high-demand markets. Investors should monitor the company's revenue contribution from international operations in upcoming quarterly reports.
Nephroplus Approves USD 6 Million Corporate Guarantee for Philippines Subsidiary
Nephrocare Health Services Limited (Nephroplus) has approved the issuance of a corporate guarantee up to USD 6.00 million in favor of Citibank N.A., Philippines. This guarantee is intended to secure working capital facilities for its step-down wholly-owned subsidiary, Nephrocare Health Care Services Philippines Inc. The commitment will be recorded as a contingent liability on the company's balance sheet. This move underscores the company's support for its international operations and growth in the Southeast Asian market.
முக்கிய அம்சங்கள்
Corporate guarantee approved for an aggregate amount not exceeding USD 6.00 millionBeneficiary is Nephrocare Health Care Services Philippines Inc., a step-down wholly-owned subsidiaryGuarantee provided to Citibank N.A., Philippines or other overseas lendersPurpose is to secure working capital facilities for the subsidiary's operationsThe guarantee will be recognized as a contingent liability for the parent company
👀 கவனிக்க வேண்டியவை
Investors should monitor the operational performance of the Philippines subsidiary to ensure it remains self-sufficient and does not trigger the guarantee. This is a standard procedure for supporting international growth but adds to the company's contingent liabilities.
Nephroplus Re-appoints Om Prakash Manchanda as Independent Director for 3-Year Term
Nephrocare Health Services (Nephroplus) has approved the re-appointment of Mr. Om Prakash Manchanda as an Independent Director for a second three-year term starting February 11, 2026. Mr. Manchanda, the former Managing Director of Dr. Lal PathLabs, brings 35 years of extensive experience in healthcare and medical science management. Additionally, the board appointed M/s Makarand M. Joshi & Co. as Secretarial Auditors for a five-year tenure from April 2025 to March 2030. These appointments are subject to shareholder approval and reflect a focus on maintaining high-caliber governance and oversight.
முக்கிய அம்சங்கள்
Mr. Om Prakash Manchanda re-appointed as Independent Director for a 3-year term until February 2029Mr. Manchanda has 35 years of experience and was previously the Managing Director of Dr. Lal PathLabsM/s Makarand M. Joshi & Co. appointed as Secretarial Auditor for a 5-year period (FY 2025-26 to 2029-30)The re-appointment is subject to shareholder approval via a special resolutionMr. Manchanda is an IIM Ahmedabad alumnus and recipient of the EY Entrepreneur of the Year award (2019)
👀 கவனிக்க வேண்டியவை
Investors should view the retention of a high-profile industry veteran like Mr. Manchanda as a positive sign for the company's strategic direction and governance. No immediate action is required as this ensures leadership continuity.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
